181 related articles for article (PubMed ID: 36330532)
21. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations.
Pla Peris B; Arranz Martin A; Ballesteros García A; Sebastián-Valles F; Marazuela Azpiroz M
Front Endocrinol (Lausanne); 2022; 13():802612. PubMed ID: 35178031
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report.
Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG
Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826
[TBL] [Abstract][Full Text] [Related]
23. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
Osafehinti DA; Okoli OJ; Karam JG
AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
[TBL] [Abstract][Full Text] [Related]
24. Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
Schutte T; Zeverijn LJ; Geurts BS; de Wit GF; Kok M; Opdam FL
Oncologist; 2023 Jul; 28(7):e493-e497. PubMed ID: 37086483
[TBL] [Abstract][Full Text] [Related]
25. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
[TBL] [Abstract][Full Text] [Related]
27. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
28. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
29. Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma.
Ahmed T; Karimi H; Hegde V; Lodhi SH
Cureus; 2021 Oct; 13(10):e19169. PubMed ID: 34873512
[TBL] [Abstract][Full Text] [Related]
30. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
31. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
Zughaib MT; Patel K; Leka M; Affas S
Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
[TBL] [Abstract][Full Text] [Related]
32. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
33. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
34. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
Rendell MS
Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
[TBL] [Abstract][Full Text] [Related]
35. ALPELISIB - INDUCED HYPERGLYCEMIA.
Ekanayake PS; Gerwer J; Mccowen K
Acta Endocrinol (Buchar); 2022; 18(1):115-117. PubMed ID: 35975254
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
Teng R; Kurian M; Close KL; Buse JB; Peters AL; Alexander CM
Diabetes Spectr; 2021 Jan; 34(1):42-51. PubMed ID: 33627993
[No Abstract] [Full Text] [Related]
37. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
38. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis.
Wasey W; Hutchings S; Dufner A; Okon D; Saleh S
Cureus; 2022 Jun; 14(6):e25788. PubMed ID: 35812537
[TBL] [Abstract][Full Text] [Related]
39. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
Liu D; Weintraub MA; Garcia C; Goncalves MD; Sisk AE; Casas A; Harding JJ; Harnicar S; Drilon A; Jhaveri K; Flory JH
Cancer Med; 2022 Apr; 11(8):1796-1804. PubMed ID: 35212193
[TBL] [Abstract][Full Text] [Related]
40. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
